Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin

James, Stefan

doi:10.3109/2000-1967-101

Cited by 3 publications

(3 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ушкалова Елена Андреевна -д.м.н., проф. кафедры; e-mail: eushk@yandex.ru тромботическим может играть важную роль в его терапевтическом действии при ОКС [10]. воспаление имеет большое значение и у пациентов, которым показано применение гепарина с целью профилактики венозной тромбоэмболии, в том числе у перенесших протезирование бедренного и коленного суставов, операции на органах брюшной полости, у больных с длительной иммобилизацией.…”

Section: контактная информацияunclassified

Enoxaparin is a low-molecular-weight heparin with a complex chemical structure and various non-anticoagulant properties

Zyryanov

Ушкалова

2016

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The paper discusses the non-anticoagulant properties of unfractionated heparin and enoxaparin and their relation to their chemical structures. It is emphasized that enoxaparin has multiple, often interrelated, non-anticoagulant effects that can complement its antithrombotic activity and enhance the efficiency of therapy in patients receiving the drug for various indications. The realization of these effects requires the complex structure with the standard distribution of molecular weight (Mw) (average Mw, about 4500 Da, as well as Mw of less than 2000 Da (<20%), 2000 to 8000 Da (>68%), and more than 8000 Da (<18%), and with the standard content of 1.6-anhidro rings (15-25%), which is determined by the source of raw materials and by the production technology of the original drug and cannot be fully reproduced when designing its bioanalogues.

show abstract

Section: контактная информацияunclassified

Enoxaparin is a low-molecular-weight heparin with a complex chemical structure and various non-anticoagulant properties

Zyryanov

Ушкалова

2016

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

“…The fact that circulating proteins associated with coagulation, fibrinolysis, protein S, protein C, antithrombin III and inflammatory factors (activated white blood cells, fibrinogen) remained associated with coronary artery disease and with recurrent thrombosis, recurrent ischemia, reinfarction and cardiovascular mortality was also demonstrated [2,3].…”

Section: Introductionmentioning

confidence: 99%

Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?

Meddahi

Samama²

2009

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

The procoagulant activity of a thrombus is essentially due to clot-associated factor IIa and factor Xa activities.The aim of this review is to underline that specific antithrombin and anti-Xa drugs, such as r-hirudin and DX 9065a, respectively, are complementary, and could be used in combination in clinical trials in patients with acute arterial thrombosis such as coronary syndromes. After standardization of the in-vitro techniques for clot-bound thrombin and clot-associated factor Xa, we have studied the anticoagulant effect of unfractionated heparin and a low-molecular heparin in an in-vitro model. We have confirmed the inability of heparins to inhibit clot-bound thrombin and clot-associated factor Xa. We have compared r-hirudin, a direct thrombin inhibitor, with DX9065a, a direct factor Xa inhibitor. We have observed that r-hirudin inhibited clot-bound thrombin but not clot-bound factor Xa. After r-hirudin treatment interruption, a hypercoagulation rebound has been reported and it could be in relation with the persistence of factor Xa activity in the clot. We have demonstrated that DX9065a inhibits clot-bound factor Xa but does not inhibit clot-bound factor IIa. The complementary effect of DX9065a and r-hirudin is demonstrated in this experimental model. It is likely that several other combinations of drugs may also exhibit an increase of the antithrombotic activity which could be of interest in clinical implication for the treatment of several groups of patients at high risk of arterial thrombosis.

show abstract

“…Inflammation and oxidative stress are usually accompanied by increased platelet activation and aggregation (3–6). Increased expression of cyclooxygenase-2 associated with inflammation may induce generation of thromboxane A2, thereby resulting in a prothrombotic state (4–6).…”

mentioning

confidence: 99%

Evaluation of inflammatory conditions associated with aspirin resistance

Yalcinkaya¹,

Çelik

2014

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin

Cited by 3 publications

References 155 publications

Enoxaparin is a low-molecular-weight heparin with a complex chemical structure and various non-anticoagulant properties

Enoxaparin is a low-molecular-weight heparin with a complex chemical structure and various non-anticoagulant properties

Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?

Evaluation of inflammatory conditions associated with aspirin resistance

Contact Info

Product

Resources

About